OBJECTIVE:Resistant maltodextrin has been shown to increase fecal bulk by resisting digestion and being partially fermented by colonic bacteria to short-chain fatty acids (SCFA). The objective of this experiment was to determine potential prebiotic effects, gastrointestinal tolerance, and fecal characteristics of free-living humans fed a novel resistant maltodextrin or a normal maltodextrin control. METHODS:Subjects (n = 38) were enrolled in a randomized, double-blind study where they were assigned to one of three daily treatments: 15 g maltodextrin; 7.5 g maltodextrin plus 7.5 g resistant maltodextrin (Fibersol-2; Matsutani Chemical Company, Hyogo, Japan); and 15 g resistant maltodextrin. The experiment lasted 7 wk and consisted of a 2 wk baseline period, a 3 wk treatment period, and a 2 wk washout period. During wk 3 to 5 (treatment period), subjects consumed their assigned treatments. RESULTS:Resistant maltodextrin supplementation tended to increase (p = 0.12) fecal Bifidobacterium populations during the treatment period, altered (p < 0.05) bacterial populations from baseline to treatment, and resulted in very minor effects in gastrointestinal tolerance. There was a shift (p < 0.05) in molar proportions of SCFA towards butyrate, the preferred energy substrate of colonocytes. CONCLUSION:Resistant maltodextrin supplementation was well tolerated, resulted in favorable fermentation characteristics in the large bowel, and also resulted in a change in bacterial populations.
RCT Entities:
OBJECTIVE: Resistant maltodextrin has been shown to increase fecal bulk by resisting digestion and being partially fermented by colonic bacteria to short-chain fatty acids (SCFA). The objective of this experiment was to determine potential prebiotic effects, gastrointestinal tolerance, and fecal characteristics of free-living humans fed a novel resistant maltodextrin or a normal maltodextrin control. METHODS: Subjects (n = 38) were enrolled in a randomized, double-blind study where they were assigned to one of three daily treatments: 15 g maltodextrin; 7.5 g maltodextrin plus 7.5 g resistant maltodextrin (Fibersol-2; Matsutani Chemical Company, Hyogo, Japan); and 15 g resistant maltodextrin. The experiment lasted 7 wk and consisted of a 2 wk baseline period, a 3 wk treatment period, and a 2 wk washout period. During wk 3 to 5 (treatment period), subjects consumed their assigned treatments. RESULTS: Resistant maltodextrin supplementation tended to increase (p = 0.12) fecal Bifidobacterium populations during the treatment period, altered (p < 0.05) bacterial populations from baseline to treatment, and resulted in very minor effects in gastrointestinal tolerance. There was a shift (p < 0.05) in molar proportions of SCFA towards butyrate, the preferred energy substrate of colonocytes. CONCLUSION: Resistant maltodextrin supplementation was well tolerated, resulted in favorable fermentation characteristics in the large bowel, and also resulted in a change in bacterial populations.
Authors: Baokun He; Kazunari Nohara; Nadim J Ajami; Ryan D Michalek; Xiangjun Tian; Matthew Wong; Susan H Losee-Olson; Joseph F Petrosino; Seung-Hee Yoo; Kazuhiro Shimomura; Zheng Chen Journal: Sci Rep Date: 2015-06-04 Impact factor: 4.379
Authors: María Salud Abellán Ruiz; María Dolores Barnuevo Espinosa; Carlos J Contreras Fernández; Antonio J Luque Rubia; Francisca Sánchez Ayllón; Miriam Aldeguer García; Carlos García Santamaría; Francisco Javier López Román Journal: Eur J Nutr Date: 2015-10-06 Impact factor: 5.614
Authors: Jessica M Moon; Peter Finnegan; Richard A Stecker; Hanna Lee; Kayla M Ratliff; Ralf Jäger; Martin Purpura; Carolyn M Slupsky; Maria L Marco; Craig J Wissent; Jason Theodosakis; Chad M Kerksick Journal: Nutrients Date: 2021-06-24 Impact factor: 5.717